|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR-OPC-17011644 |
|
最近更新日期: Date of Last Refreshed on: |
2017-06-13 11:20:10 |
|
注册时间: Date of Registration: |
2017-06-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
速效救心丸治疗慢性稳定型冠心病心绞痛前瞻性社区队列研究 |
|
Public title: |
Prospective Community Cohort Study of Chronic Stable Angina Pectoris Treated with Suxiao Jiuxin Wan |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
速效救心丸治疗慢性稳定型冠心病心绞痛前瞻性社区队列研究 |
|
Scientific title: |
Prospective Community Cohort Study of Chronic Stable Angina Pectoris Treated with Suxiao Jiuxin Wan |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李和林 |
研究负责人: |
林谦 |
|
Applicant: |
Li Helin |
Study leader: |
Lin Qian |
|
申请注册联系人电话: Applicant telephone: |
+86 13693297970 |
研究负责人电话: Study leader's telephone: |
+86 13910565673 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
569510851@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
13910565673@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市朝阳区慧忠北里105号B段京师科技大厦5层 |
研究负责人通讯地址: |
北京丰台方庄芳星园一区6号 |
|
Applicant address: |
5th Floor, Jingshi Sci-Tech Plaza, Block B, 105 Huizhong North Street, Chaoyang District, Beijing, China |
Study leader's address: |
6 Fangxingyuan 1st Block, Fengtai District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
北京康派特药物研究与临床评价中心 |
||
|
Applicant's institution: |
Beijing COMPETE Pharmaceutical Research and Clinical Evaluation Center |
||
|
研究负责人所在单位: |
北京中医药大学东方医院 |
||
|
Affiliation of the Leader: |
Dongfang Hospital Affiliated to Beijing University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
JDF-IRB-2017030701 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
北京中医药大学东方医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
IRB of Dongfang Hospital Affiliated to Beijing University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 |
||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
北京中医药大学东方医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Dongfang Hospital Affiliated to Beijing University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京丰台方庄芳星园一区6号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
6 Fangxingyuan 1st Block, Fengtai District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
天津中新药业集团股份有限公司第六中药厂 |
||||||||||||||||||||||
|
Source(s) of funding: |
Tianjin Sixth Traditional Chinese Medicine Factory of Zhongxin Pharmaceuticals Group Co., Ltd |
||||||||||||||||||||||
|
Target disease: |
Chronic Stable Angina Pectoris |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
上市后药物 | ||||||||||||||||||||||
|
Study phase: |
4 |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1、主要目的: 1) 评估速效救心丸临床实际应用治疗慢性稳定型冠心病心绞痛的即刻疗效,即心绞痛缓解时间; 2) 评估速效救心丸临床实际应用治疗慢性稳定型冠心病心绞痛对患者心绞痛发作次数、严重程度、持续时间以及硝酸甘油用量等的影响; 3) 以麝香保心丸、复方丹参滴丸作为对照评估速效救心丸治疗慢性稳定型冠心病心绞痛的经济性; 4) 评估速效救心丸实际临床应用的安全性。 2、次要目的: 1) 评估速效救心丸在临床实际应用治疗慢性稳定型冠心病心绞痛对患者心血管事件发生的影响; 2) 评估速效救心丸实际应用过程中不同人群和亚组人群的临床疗效特征(实际使用方法、剂量、用药时间等效果异质性差异); 3) 建立速效救心丸临床实际应用医院登记的研究、质控、数据管理和统计分析平台,长期积累临床数据,不断挖掘速效救心丸的临床疗效优势,监测安全性数据,为速效救心丸的实际临床应用提供可靠数据支持; 4) 以复方丹参滴丸、麝香保心丸为对照,评价速效救心丸治疗慢性稳定型冠心病心绞痛的临床作用不同特点; 5) 通过社区监测及宣贯,进一步扩大速效救心丸的影响力,让医生和患者充分了解速效救心丸的合理使用方法; 6) 撰写并不断改进速效救心丸实际用药指南。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.Primary objectives: 1) To evaluate the immediate effect of Suxiao Jiuxin Wan in treatment of chronic stable angina pectoris, i.e., time of remission of angina pectoris; 2) To evaluate the impact of Suxiao Jiuxin Wan on frequency, severity, duration of angina pectoris and dosage of nitroglycerin in patients with chronic stable angina pectoris treated; 3) To evaluate the economy of Suxiao Jiuxin wan in treatment of chronic stable angina pectoris, in which Shexiang Baoxin Wan and Compound Danshen Dripping Pill are taken as a control; 4) To evaluate the safety of Suxiao Jiuxin Wan in clinical treatment. 2. Secondary objectives: 1) To evaluate the effect of Suxiao Jiuxin Wan on cardiovascular events in patients with chronic stable angina pectrois in clinical treatment; 2) To evaluate the clinical efficacy characteristics of Suxiao Jiuxin Wan in different groups and subgroups of patients in clinical treatment (heterogeneous differences in actual usage, dosage, time of medication and so forth); 3) To establish a platform of Suxiao Jiuxin Wan in clinical treatment used for hospital registration research, quality control, data management and statistical analysis, have a long-term accumulation of clinical data, constantly tap the advantages of Suxiao Jiuxin wan, monitor safety data, so as to provide reliable data support for clinical treatment of Suxiao Jiuxin Wan; 4) To evaluate different clinical characteristics of Suxiao Jiuxin Wan in treatment of chronic stable coronary angina pectoris, in which Shexiang Baoxin Wan and Compound Danshen Dripping Pill are taken as a control; 5) To further expand the influence of Suxiao Jiuxin Wan through community monitoring and public promotion, so as to let doctors and patients fully understand its use; 6) To compile and constantly improve the guide for medication of Suxiao Jiuxin Wan. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 符合慢性稳定型冠心病心绞痛的诊断,且曾在二级及二级以上医院明确被诊断为慢性稳定型冠心病心绞痛; |
||||||||||||||||||||||
|
Inclusion criteria |
1. Diagnosed by the secondary or above hospital as chronic stable angina pectoris; |
||||||||||||||||||||||
|
排除标准: |
无 |
||||||||||||||||||||||
|
Exclusion criteria: |
Non |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2017-04-26 00:00:00至 To 2018-09-18 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2017-06-19 00:00:00 至 To 2017-08-18 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验完成后6个月内公开;各研究中心 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
within six months after the trial complete;every study center. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据原始资料保存于各研究中心;数据记录采用纸质和电子版病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data is collected by clinical recording fomula (both paper and electronic version) |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |